

# Olof Bengtsson

## List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/7810801/publications.pdf>

Version: 2024-02-01

19  
papers

7,278  
citations

516215

16  
h-index

794141

19  
g-index

19  
all docs

19  
docs citations

19  
times ranked

7457  
citing authors

#	ARTICLE	IF	CITATIONS
1	Initial Decline (Dip) in Estimated Glomerular Filtration Rate After Initiation of Dapagliflozin in Patients With Heart Failure and Reduced Ejection Fraction: Insights From DAPA-HF. <i>Circulation</i> , 2022, 146, 438-449.	1.6	53
2	Efficacy and Safety of Dapagliflozin According to Frailty in Heart Failure With Reduced Ejection Fraction. <i>Annals of Internal Medicine</i> , 2022, 175, 820-830.	2.0	56
3	Design and Analysis of Studies Based on Hierarchical Composite Endpoints: Insights from the DARE-19 Trial. <i>Therapeutic Innovation and Regulatory Science</i> , 2022, 56, 785-794.	0.8	9
4	Effects of Dapagliflozin According to the Heart Failure Collaboratory Medical Therapy Score. <i>JACC: Heart Failure</i> , 2022, 10, 543-555.	1.9	7
5	Efficacy of Dapagliflozin on Renal Function and Outcomes in Patients With Heart Failure With Reduced Ejection Fraction. <i>Circulation</i> , 2021, 143, 298-309.	1.6	193
6	Dapagliflozin in HFrEF Patients Treated With Mineralocorticoid Receptor Antagonists. <i>JACC: Heart Failure</i> , 2021, 9, 254-264.	1.9	75
7	Extrapolating Long-term Event-Free and Overall Survival With Dapagliflozin in Patients With Heart Failure and Reduced Ejection Fraction. <i>JAMA Cardiology</i> , 2021, 6, 1298-1305.	3.0	12
8	Effect of dapagliflozin on ventricular arrhythmias, resuscitated cardiac arrest, or sudden death in DAPA-HF. <i>European Heart Journal</i> , 2021, 42, 3727-3738.	1.0	125
9	Dapagliflozin and the Incidence of Type 2 Diabetes in Patients With Heart Failure and Reduced Ejection Fraction: An Exploratory Analysis From DAPA-HF. <i>Diabetes Care</i> , 2021, 44, 586-594.	4.3	50
10	Efficacy and Safety of Dapagliflozin in Heart Failure With Reduced Ejection Fraction According to N-Terminal Pro-B-Type Natriuretic Peptide: Insights From the DAPA-HF Trial. <i>Circulation: Heart Failure</i> , 2021, 14, CIRCHEARTFAILURE121008837.	1.6	21
11	Effects of Dapagliflozin on Symptoms, Function, and Quality of Life in Patients With Heart Failure and Reduced Ejection Fraction. <i>Circulation</i> , 2020, 141, 90-99.	1.6	244
12	Effect of Dapagliflozin on Outpatient Worsening of Patients With Heart Failure and Reduced Ejection Fraction. <i>Circulation</i> , 2020, 142, 1623-1632.	1.6	51
13	Effect of dapagliflozin according to baseline systolic blood pressure in the Dapagliflozin and Prevention of Adverse Outcomes in Heart Failure trial (DAPA-HF). <i>European Heart Journal</i> , 2020, 41, 3402-3418.	1.0	90
14	Effects of dapagliflozin in DAPA-HF according to background heart failure therapy. <i>European Heart Journal</i> , 2020, 41, 2379-2392.	1.0	151
15	The Dapagliflozin And Prevention of Adverse Outcomes in Heart Failure (DAPA-HF) trial: baseline characteristics. <i>European Journal of Heart Failure</i> , 2019, 21, 1402-1411.	2.9	159
16	Dapagliflozin in Patients with Heart Failure and Reduced Ejection Fraction. <i>New England Journal of Medicine</i> , 2019, 381, 1995-2008.	13.9	4,108
17	Efficacy and safety with ticagrelor in patients with prior myocardial infarction in the approved European label: insights from PEGASUS-TIMI 54. <i>European Heart Journal - Cardiovascular Pharmacotherapy</i> , 2019, 5, 200-206.	1.4	25
18	A trial to evaluate the effect of the sodium-glucose co-transporter 2 inhibitor dapagliflozin on morbidity and mortality in patients with heart failure and reduced left ventricular ejection fraction (DAPA-HF). <i>European Journal of Heart Failure</i> , 2019, 21, 665-675.	2.9	264

#	ARTICLE	IF	CITATIONS
19	Long-Term Use of Ticagrelor in Patients with Prior Myocardial Infarction. New England Journal of Medicine, 2015, 372, 1791-1800.	13.9	1,585